Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

9 Meters Biopharma, Inc. MNTRQ

Healthcare  —  Biotechnology
Market cap
$1.0M
P/E
0.0×
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

9 Meters Biopharma, Inc. (MNTRQ) Business Profile

Updated before January 2025

Company Overview

9 Meters Biopharma, Inc. (MNTRQ) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare and unmet medical needs, particularly in the field of gastroenterology. The company was founded in 2012 and is headquartered in Raleigh, North Carolina. Over the years, 9 Meters Biopharma has established itself as a leader in the development of treatments for gastrointestinal diseases, leveraging its expertise in drug development and clinical research.

The company is led by a team of experienced professionals in the biopharmaceutical industry. John Temperato serves as the President and Chief Executive Officer, bringing decades of experience in healthcare and pharmaceutical leadership. The leadership team also includes key figures such as Dr. Patrick Griffin, Chief Medical Officer, who oversees the clinical development of the company’s pipeline, and Dr. Michael Rice, Chief Scientific Officer, who drives the company’s research and innovation efforts.

Core Business Segments

9 Meters Biopharma focuses on developing therapies for gastrointestinal diseases and rare conditions. The company’s core business segments include:

Gastrointestinal Disorders

  • Larazotide: A first-in-class oral peptide being developed for celiac disease. Larazotide is designed to reduce symptoms in patients who continue to experience issues despite adhering to a gluten-free diet. It is currently in late-stage clinical trials.
  • NM-102: A therapeutic candidate targeting short bowel syndrome (SBS), a condition that results from the surgical removal of a large portion of the small intestine.

Rare and Orphan Diseases

  • NM-003: A long-acting GLP-1 receptor agonist being developed for rare gastrointestinal conditions. This product aims to address unmet needs in the treatment of conditions such as SBS and other rare disorders.

Supportive Care

  • NM-004: A candidate designed to address gastrointestinal complications associated with cancer treatments, such as chemotherapy-induced diarrhea.

Business Model

9 Meters Biopharma operates as a clinical-stage biopharmaceutical company, focusing on the research, development, and commercialization of innovative therapies. The company’s business model revolves around:

  • Research and Development (R&D): A significant portion of the company’s resources is allocated to R&D activities, including preclinical studies and clinical trials.
  • Partnerships and Collaborations: The company collaborates with academic institutions, research organizations, and other biopharmaceutical companies to advance its pipeline.
  • Revenue Generation: While the company is not yet generating significant revenue from product sales, it aims to commercialize its therapies upon regulatory approval.

Strategic Direction

9 Meters Biopharma is committed to addressing unmet medical needs in gastroenterology and rare diseases. The company’s strategic priorities include:

  • Advancing Clinical Pipeline: The company is focused on progressing its lead candidates, such as Larazotide and NM-003, through clinical trials and toward regulatory approval.
  • Expanding Therapeutic Areas: 9 Meters Biopharma aims to explore additional indications for its existing pipeline and develop new therapies for related conditions.
  • Sustainability Goals: The company is dedicated to sustainable practices in its operations and aims to minimize its environmental impact.

Competitive Landscape

9 Meters Biopharma operates in a competitive biopharmaceutical landscape, with key competitors including:

  • Takeda Pharmaceuticals: A global leader in gastroenterology, offering treatments for conditions such as inflammatory bowel disease (IBD).
  • AbbVie: Known for its blockbuster drug Humira, which is used to treat Crohn’s disease and ulcerative colitis.
  • Amgen: A major player in the biopharmaceutical industry, with a focus on innovative therapies for gastrointestinal and inflammatory diseases.
  • Smaller Biotech Firms: Companies such as Protagonist Therapeutics and Seres Therapeutics are also developing therapies for gastrointestinal disorders.

Risk Factors

Like any clinical-stage biopharmaceutical company, 9 Meters Biopharma faces several risks, including:

  • Regulatory Risks: The success of the company’s pipeline depends on obtaining regulatory approvals, which can be uncertain and time-consuming.
  • Market Dependence: The company’s future revenue is heavily reliant on the successful commercialization of its lead candidates.
  • Supply Chain Disruptions: Delays or disruptions in the supply chain could impact the company’s ability to conduct clinical trials or manufacture products.
  • Financial Risks: As a clinical-stage company, 9 Meters Biopharma relies on external funding and may face challenges in securing additional capital.

Recent Developments

In recent months, 9 Meters Biopharma has made significant progress in advancing its clinical pipeline. Key developments include:

  • Larazotide Clinical Trials: The company announced positive interim results from its Phase 3 clinical trial for Larazotide, demonstrating its potential to improve symptoms in celiac disease patients.
  • Partnerships: 9 Meters Biopharma entered into a collaboration with a leading research institution to explore new applications for its pipeline.
  • Corporate Strategy: The company implemented cost-saving measures to optimize its operations and extend its financial runway.

Investment Considerations

Investors considering 9 Meters Biopharma should weigh the following factors:

Strengths

  • Innovative Pipeline: The company’s focus on unmet medical needs positions it as a leader in the gastroenterology space.
  • Experienced Leadership: The management team has a proven track record in drug development and commercialization.
  • Market Potential: The global market for gastrointestinal therapies is growing, providing significant opportunities for the company.

Risks

  • Clinical and Regulatory Uncertainty: The success of the company’s pipeline is not guaranteed and depends on clinical trial outcomes and regulatory approvals.
  • Financial Dependence: The company’s reliance on external funding poses a risk if additional capital cannot be secured.
  • Competitive Pressure: The biopharmaceutical industry is highly competitive, with larger players dominating the market.

Conclusion

9 Meters Biopharma is a promising clinical-stage biopharmaceutical company with a strong focus on addressing unmet medical needs in gastroenterology and rare diseases. While the company faces challenges typical of its industry, its innovative pipeline, experienced leadership, and strategic direction position it for potential success. As the company advances its clinical programs and explores new opportunities, it remains a compelling option for investors seeking exposure to the biopharmaceutical sector.